Analyst Mayank Mamtani of B.Riley Financial reiterated a Buy rating on Trevi Therapeutics (TRVI ... underpin Mamtani’s optimistic outlook and support his Buy recommendation for the stock.

Marc Frahm’s rating is based on a combination of factors that highlight Repare Therapeutics’ promising potential. The company has reported significant progress in its clinical oncology ...

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics ... of choline for adult and adolescent patients on parenteral support (PS) for whom oral or enteral nutrition is not possible ...

Seaport Therapeutics, the startup launched earlier this year by the team behind Karuna Therapeutics, has raised another $225 million just six months after its most recent fundraising round.

This Commercial Readiness Pilot (CRP) Program SBIR award will also support Phase 2 clinical GMP manufacturing to advance Rise Therapeutics' R-3750 program currently completing a Phase 1 proof-of ...

Viking Therapeutics (NASDAQ:VKTX) added ~18% on Thursday to reach a five-month high as Wall Street focused on updates on its obesity candidate VK2735, even as the company posted better-than ...

Plantsulin is a recently launched glucose control supplement that arrived in the world market arena. It is developed b ...

Remain on track to initiate registrational THRIVE-3 trial in 1Q' 2025 NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics ... patients on parenteral support (PS) for whom oral ...

as an important novel modality to treat IgAN Data support progression towards a Phase I/II clinical trial London – 28 October 2024 - Purespring Therapeutics, a pioneering gene therapy company ...

DUBLIN and CHICAGO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq ... Patients with known blood dyscrasias. Patients with known uric acid kidney stones. Concomitant use ...